EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Extended Versus Standard Hypomethylating Agent Dosing in Combination With Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia

Georgio Medawar iD, Jean-Sebastien Anoma, Elizabeth Hill iD, Serena Tharakan, Dahniel L Sastow, Vincent Lok iD, Su Bin Hahn, Sarah Chen, Thomas Kehoe, Chidambaram Ramasamy, Julian Guetta-Weiss, Kapil Meleveedu und 4 weitere

Hematological Oncology · 2026

DOI: 10.1002/hon.70198 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Hematological Oncology, 2026. Verfasst von Georgio Medawar und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology-Oncology, Medical University of South Carolina, Charleston, South Carolina, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Sulfonamides, Antineoplastic Combined Chemotherapy Protocols, DNA Methylation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The optimal duration of hypomethylating agent (HMA) therapy combined with venetoclax (Ven) in newly diagnosed acute myeloid leukemia (ND‐AML) remains uncertain. Standard of care (SOC) uses 5‐day decitabine (Dec‐5) or 7‐day azacitidine (Aza‐7), while extended HMA regimens (e.g., 10‐day decitabine [Dec‐10] during cycle 1) have also been explored, although direct comparative data between these approaches are limited. We conducted a large retrospective analysis of 335 patients with ND‐AML treated at five US centers with Dec‐10/Ven ( n = 102) or SOC HMA/Ven ( n = 233). Baseline characteristics were largely balanced, though the Dec‐10 group had more treated secondary AML, and the SOC group had more intermediate risk by ELN‐2024. Dec‐10/Ven exhibited significantly higher composite complete remission rates (CRc) (82% vs. 70%, p = 0.029), but similar measurable residual disease (MRD) negativity rates (27% vs. 25%, p = 0.6) at best response. Median overall survival (OS) was significantly longer for Dec‐10/Ven, 22.2 versus 9.1 months for SOC ( p < 0.001). Transplantation was more frequent following Dec‐10/Ven (25% vs. 6%, p < 0.001). The 30‐day and 60‐day mortality rates were similar (7% vs. 11%, p = 0.4; 13% vs. 23%, p = 0.1). On multivariable analysis, the Dec‐10 regimen, de novo AML, non‐complex karyotype, and IDH2 mutation were associated with a significantly lower risk of death. Our findings suggest that Dec‐10/Ven may lead to improved transplant rates and survival, providing valuable real‐world support for this intensified approach in appropriate patients. Prospective randomized evaluation is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteSulfonamidesAntineoplastic Combined Chemotherapy ProtocolsDNA MethylationHumansBridged Bicyclo Compounds, HeterocyclicFemaleMaleMiddle AgedAgedRetrospective StudiesDecitabineAdultAged, 80 and overAzacitidine

Stichwörter der Autor:innen

acute myeloid leukemiaazacitidinedecitabinedurationoutcomes

Substanzen

venetoclaxBridged Bicyclo Compounds, HeterocyclicSulfonamidesDecitabineAzacitidine

Autor:innen und Institutionen

  • Department of Hematology-Oncology, Medical University of South Carolina, Charleston, South Carolina, USA.
  • Department of Public Health, Biostatistics Shared Resources, Medical University of South Carolina, Charleston, South Carolina, USA.
  • Department of Hematology-Oncology, Weill Cornell Medicine, New York, New York, USA.
  • Department of Hematology-Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Department of Medicine, University of South Florida Morsani College of Medicine, Tampa, Florida, USA.
  • Department of Family & Community Medicine, University of California San Francisco, San Francisco, California, USA.

ORCID-Profile: Georgio Medawar, Elizabeth Hill, Vincent Lok, Chenyu Lin

Zitieren

APA

Medawar, G., Anoma, J. S., Hill, E., Tharakan, S., Sastow, D. L., Lok, V., Hahn, S. B., Chen, S., Kehoe, T., Ramasamy, C., Guetta-Weiss, J., Meleveedu, K., Lin, C., Swoboda, D. M., Tremblay, D., & Coltoff, A. (2026). Extended Versus Standard Hypomethylating Agent Dosing in Combination With Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia. Hematological Oncology. https://doi.org/10.1002/hon.70198

Vancouver

Medawar G, Anoma JS, Hill E, Tharakan S, Sastow DL, Lok V, et al. Extended Versus Standard Hypomethylating Agent Dosing in Combination With Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia. Hematological Oncology. 2026. doi:10.1002/hon.70198

BibTeX
@article{Medawar2026,
  author = {Medawar, Georgio and Anoma, Jean-Sebastien and Hill, Elizabeth and Tharakan, Serena and Sastow, Dahniel L and Lok, Vincent and Hahn, Su Bin and Chen, Sarah and Kehoe, Thomas and Ramasamy, Chidambaram and Guetta-Weiss, Julian and Meleveedu, Kapil and Lin, Chenyu and Swoboda, David M and Tremblay, Douglas and Coltoff, Alexander},
  title = {Extended Versus Standard Hypomethylating Agent Dosing in Combination With Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia},
  journal = {Hematological Oncology},
  year = {2026},
  doi = {10.1002/hon.70198}
}
Kostenlos starten →